Intravitreal anti-VEGF agents have safely been used in young patients to treat a wide variety of chorioretinal diseases over long periods of follow-up24, with no definite systemic or neurodevelopmental comorbidities identified, even in premature infants25. This evidence concerns the gene VEGFA and chorioretinitis.